Volume 9, Issue 2, February – 2024 International Journal of Innovative Science and Research Technology

ISSN No:-2456-2165

Review on Implementation of Quality by Design

Jinal A Goswami, Zeel. M. Modi Khushbu Patel, Dr. C.N. Patel
Department of Quality Assurance, Department of Quality Assurance
Shri Sarvajanik Pharmacy College, Shri Sarvajanik Pharmacy College,
Mehsana 384001, Gujrat, India Mehsana 384001, Gujrat, India

Abstract:- The Pharmaceutical Quality By Design (QbD)  Stage 3 Continued method verification: Gain
is a systemic approach to the development that starts continuous affirmation to guarantee that the strategy
with the predetermined objectives and is based on the stays in a condition of control during routine use.
process of understanding process processes and process
control, sound science and quality risk management. A basic capacity of stage 1 is the plan of an Analytical
Quality Design has been created to increase the assured Target Profile (ATP) for the strategy. To plan the ATP, it is
of providing safe, effective medicines to customers and important to decide the qualities that will be marks of
promised to make significant improvements in product technique execution for its planned use. These are chosen
quality performance. from the exhibition attributes descried in ICHQ2 according
to the customary methodology. Rather than being applied in
Keywords:- Quality by Design, Quality Target Product, a mark box way, they are explored by a danger evaluation
Critical Quality Attributes. practice as portrayed in ICHQ9 in mix with painstakingly
planned improvement studies to distinguish the basic
I. INTRODUCTION [1-5] technique and well springs of variety.

The articulation "Quality by Design" alludes to the II. IMPLEMENTATION OF QBD APPROACH
accomplishment of a characterized and reliable degree of
value. Getting factors and their connections across an ideal According to ICH Q8 (R2) guidelines, an experimental
series of examinations, called an Experimental Design, is an work was planned and QbD approach was implemented as
exceptionally helpful part of the QbD. follows

Quality by Design standards have been utilized to A. Method Design

propel item and interaction quality in each industry, they The technique configuration stage incorporates
have most as of late been taken on by the United States building up the strategy execution prerequisites, fostering a
Food and Drug Administration (USFDA) as a vehicle for the technique that will meet these necessities and afterward
change of how medications are found, created, and performing suitable examinations to comprehend the basic
monetarily made. Since, first started by the United States technique factors that should be controlled to guarantee the
Food and Drug Administration (USFDA) in its "Drug strategy is hearty and rough.
cGMPs for the twenty-first century". It has turned into a
significant idea for the drug business that is additionally  Method Performance Requirements
characterized in the International Council for Harmonization Using a QbD approach, it is fundamental at this stage
(ICH) direction. that adequate idea be given to the expected utilization of the
strategy and that the destinations or execution prerequisites
A. Definition according to (ICHQ8(R1)) of the technique be completely archived. This addresses the
“A methodical way to deal with development that Analytical Target Profile (ATP) for the strategy. ATP is the
beginnings with predefined objectives and accentuates item assessment of Active Pharmaceutical Ingredient (API) in
and interaction understanding and guideline, all while tablet measurement structure utilizing spectrophotometric
clinging to sound science and quality danger the executives." and/or chromatographic techniques. Logical Target Profile
(ATP) which is like the Quality Target Product/Process
B. "Quality isn't setup in Quality Control however it is Profile (QTPP) for the Pharmaceutical Process. This ATP
inbuilt in technique improvement" will be a bunch of models that characterizes what will be
In arrangement with the methodology proposed in the estimated, in which grid, over what fixation range, and the
draft FDA direction for process approval, a three- stage necessary presentation measures of the technique, along
approach can be applied to strategy approval. with details for these last ones. These exhibition measures
can be called Critical Quality Attributes (CQAS).
 Stage1 Method design: Define strategy necessity and
conditions and distinguish basic controls.  Method Development
 Stage 2 Method qualification: Confirm that the strategy When the ATP has been characterized, a suitable
is equipped for meeting its plan aim. procedure and technique condition should be chosen all
together meet theprerequisites of the ATP.

IJISRT24FEB293 www.ijisrt.com 544

Volume 9, Issue 2, February – 2024 International Journal of Innovative Science and Research Technology
ISSN No:-2456-2165
 Method understanding execution approach with FDA before accommodation,
In view of an appraisal of hazard one can play out an while if there should arise an occurrence of conventional
activity zeroed in on understanding the strategy to more methodology it isn't needed by administrative body.
readily get what effect key info factors may have on the
technique's presentation attributes. From this, one can B. Design of Experiment (DOE)
recognize a bunch offunctional technique controls.
 Introduction to design of experiments:
B. Risk Assessment It is the procedure of how to direct and design tests to
Investigations can be rushed to comprehend the remove the greatest measure of data in the least number of
practical connection between technique input factors and runs.
every one of the strategy execution qualities. Information
aggregated during the turn of events and starting utilization  Plan of Experiment (DoE) is a helpful instrument for
of the strategy gives input into a danger evaluation (utilizing investigation of configuration space and is a fundamental
apparatuses, for example, the Fishbone chart, FMEA and piece of Quality by Design (QbD) tool compartment.
Ishikawa Diagram) which might be utilized to figure out
which factors need considering and which require controls.  It offers a few advantages throughout each element in
turn (OFAT) test, including the synchronous
III. DESIGN OF EXPERIMENTS investigation of different elements.

Power tests are commonly performed on parametric  It gives an organized investigation of fundamental
factors utilizing Design of Experiment (DoE) to guarantee impacts, various component association and commotion.
that greatest arrangement is acquired while limiting the
absolute number of examinations. Contingent upon the kind  It can concentrate on different scientific difficulties like
of strategy, proxy proportions of attributes, for example, agreement factor that impact development of debasement
exactness or accuracy might be assessed. It did for meaning items in arrangement and HPLC streamlining.
of Critical Parameters as the after effects of the danger
evaluation, the most influencing boundaries are advanced  Technique streamlining is frequently separated into
which are emphatically influencing on strategy execution. screeningand advancement stages.
A. Method Design Output  In the screening step, many variables, possibly
A bunch of technique conditions will have been created influencing the partition, are screened to recognize those
and characterized which are relied upon to meet the ATP. with the biggest impacts.
Those conditions will have been upgraded dependent on
comprehension of their effect on strategy execution. QbD-  These are then additionally inspected in an improvement
based treatment of the strength of a scientific strategy stage, to decide the best detachment condition.
requires the evaluation, everything being equal (factors)
which most firmly impact selectivity (results) alone and in
mix. The test check of many factors all the while is illogical
and related with outrageous specialized challenges and cost.
A few creators, have utilized factual examinations, for
example, Placket- Burman or partial factorial plans and
hazard based ways to deal with beat the difficulties and
decrease the exploratory responsibility. Different methods
incorporate running mechanized strength tests.

 Advantages of QbD approach over traditional approach

 Quality is incorporated into item and interaction by plan
and in light of logical agreement, while Quality is
guaranteed by testing and investigation in conventional
methodology.
 QbD approach centers around strength which
comprehends and control variety, while customary
methodology centers around reproducibility which
frequently dodges or disregards variety.
 In QbD approach any particulars dependent on item
execution necessities, while if there should be an
occurrence of conventional methodology any
determinations depend on group history.
 FDA has supported some NDA applications applying
QbD way to deal with logical techniques (for example Fig 1 Key elements of QbD
HPLC and UV). Candidates are urged to examine QbD

IJISRT24FEB293 www.ijisrt.com 545

 Volume 9, Issue 2, February – 2024 International Journal of Innovative Science and Research Technology
ISSN No:-2456-2165
C. Advantages of Doe Over Conventional of at Approach:  Control Strategy
 Fundamental style of examination Require less number  Risk based decision
ofpreliminaries  Continuous Improvement
 Set aside less effort for research
 Anticipate the expansion
 Product performance
 Genuinely and experimentally demonstrated
 Seven steps of quality by design start up plan
 Supported and intelligent method of examination
 Hire an independent Quality by design expert
 Required less endeavors and Economical Identify the
 Audit your organization and process with the expert
critical variable and irrelevant variable
conducting a gape analysis.
 Give more data including fundamental impact,
 Hold a basic quality by design workshop with all
communication impact and soon
your personal.
 Helps in working on nature of item or cycle When
 Review the expert’s report and recommendation.
fostering a technique to isolate and evaluate
 Draft an implementation plan, timelines and estimated
compound(s) in a given network, various advances are
costs.
embraced.
 Assign the resources (or contract out).
 A method is chosen
 Retain the independent expert as your “Project
 The strategy is improved and the technique is approved
Assuranceadvisor.
 Types of Experimental Design:
 QbD By Pharmaceuticals [9-13]
Selection of tests relies upon level of information
Even though the pharmaceutical industry has focus on
before tests, asset accessible and targets of the analysis
quality,it has failed to keep up with other industries in terms
Discovering significant interaction factors:
ofmanufacturing efficiency and productivity.
 Placket-Burman Fractional Factorial
 Current scenario in the Pharmaceutical Industry:
 Estimating the impact and cooperation of a few
 Cost of revalidation
variables
 Off‐line analysis for in‐process ‐ need based
 Full Fractional Factorial
 Product specifications as primary means of control
 For enhancement
 Unpredictable Scale‐up issues
 Central Composite Design (CCD)Simplex lattice
 Inability to understand failures
 D-optimal and Box Behnken (BBD)
 Systematic approach to development:
For advancement of technique by reaction surface
 That begins with predefined objectives
planapproach, the accompanying advances are performed:
 Emphasizes products and process understanding
 Choice of the reaction surface plan.
 Process control
 Meaning of the reactions Planning and execution of
theexploratory set-up and assurance of the reactions.
 Benefits of Implementing QbD For FDA[14-15]
 Building the polynomial model(s) depicting the
 Provides for better coordination across review,
relationship(s) between the response(s) and the variables.
inspection
Graphical and additionally measurable assessment of
themodel.  Improves information in regulatory submissions
 Assurance of the ideal.  Provides for better consistency
 Improves quality of review
IV. STEPS INVOLVED IN QUALITY BY DESIGN  Provides for more flexibility in decision making
PRODUCTS [6-8]  Ensures decisions made on science and not on
information
 Development of new molecular entity  Involves various disciplines in decision making
 Preclinical study  Uses resources to address higher risks
 Nonclinical study
 Clinical Study  Benefits to Industry
 Scale up  Ensures better design of products with less problems in
 Submission for market Approval manufacturing
 Reduces number of manufacturing supplements required
 Manufacturing for post market changes –rely on process and risk
understanding and risk mitigation
 Design Space
 Allows for implementation of new technology to
 Process Analytical Technology improvemanufacturing without regulatory scrutiny
 Real time Quality Control  Allows for possible reduction in overall costs of
manufacturing –less waste
 Ensures less hassle during review –reduced deficiencies
–quicker approvals

IJISRT24FEB293 www.ijisrt.com 546

Volume 9, Issue 2, February – 2024 International Journal of Innovative Science and Research Technology
ISSN No:-2456-2165
 Improves interaction with FDA –deal on a science level REFERENCES
instead of on a process level
 Allows for continuous improvements in products and [1]. Bhatt DA and Rane SI, “QbD approach to analytical
manufacturing process. RP-HPLC method development and its Validation.”
Int. J. Pharma. & Pharma. Sci. 2011, 3(10), 179- 187.
 Benefits of QBD [16-19] [2]. Jadhav ML and Tambe SR, “Implementation of QbD
approach to analytical method development and
 QbD is good Business
validation for the estimation of Propafenone
 Eliminate batch failures
Hydrochloride in tablet dosage form.” Chrsom. Res.
 Minimize deviations and costly investigations Int. 2013, 4(11),120-127.
 Avoid regulatory compliance problems [3]. Nadapara NP, Thumar RV, et al, “Quality by Design
 Organizational learning is an investment in the future (QbD): A Complete review.” Int.J. Pharma. Sci. Rev.
 QbD is good Science Res. 2011, 17 (2), 20-28.
 Better development decisions [4]. Roy S. “Quality by design: A holistic concept of
 Empowerment of technical staff building quality in pharmaceuticals.” Int. J. Pharma.
Bio. Res. 2012, 3(2), 100-108.
 Opportunities [20-21] [5]. Patel VP., and Shihora HD., Experimental Design &
 Efficient, agile, flexible system Patent; 1st Edn; Akshat publication, 2011, pp 1-35.
 Increase manufacturing efficiency, reduce costs and [6]. Callis JB, Illman DL, Kowalski BR, Process analytical
project rejections and waste chemistry. Analytical Chemistry, 59, 1987, 624A–
 Build scientific knowledge base for all products 637A.
 Better interact with industry on science issues [7]. Yu LX, Pharmaceutical quality by design: Product
 Ensure consistent information and process development, understanding, and control.
 Incorporate risk management Pharmaceutical Research, 25, 2008, 781–791.
[8]. Priya B. Shah Khushbu Patel. Qbd – A novel setup for
V. CONCLUSION the analytical method development. World Journal of
Pharmacy and Pharmaceutical
QbD is increasingly becoming an important and widely Sciences.2021;10(5):1645-1662.
used technique in pharmaceutical product development. [9]. Divyesh Sharma, Khushbu Patel and Dr. C. N. Patel.
While QbD is most effective when it is employed at a QbD-A new era of Pharmaceutical drug development
product/process design level, it should also be accomplished European Journal of Pharmaceutical and Medical
in the manufacturing and quality assurance environments. Research. 2021; 8(5):688-694.
Implementing QbD concept in product development provide [10]. Payal Chauhan, Dhruvi Modi, Mansuri Seemabanu,
quality medicines to patients, production improvements to Savitree Giri, Anjali Rathod, Khushbu K. Patel, Dr. C.
Manufacturers with significantly reduced batch failures and N. Patel. Review on analytical quality by design and
drug regulatory bodies will have greater confidence in the pat. World Journal of Pharmaceutical Research.
robust quality of products. This approach allows the 2022;11(14):244-266.
establishment of priorities and flexible boundaries in the [11]. Munson J, Gujral B, Stanfield CF, A review of process
process. As such QbD is becoming a promising scientific analytical technology (PAT) in the U.S.
tool in quality assurance in pharmaceutical industry. The pharmaceutical industry. Current Pharmaceutical
changes in product and process can be managed better Analysis, 2, 2006, 405–414
with QbD. Manufacturers can execute certain changes [12]. Munson J, Gujral B, Stanfield CF, A review of process
without filing prior approval supplements and can simply analytical technology (PAT) in the U.S.
notify regulatory authority in annual reports. The economic pharmaceutical industry. Current Pharmaceutical
and resource drain due to exhaustive validation requirements Analysis, 2, 2006, 405–414
can significantly be minimized. The application of QbD [13]. Leuenberger H, Puchkov M, Krausbauer E, Betz G,
principles can change the chemistry, manufacturing, and Manufacturing pharmaceutical granules, Is the
control regulatory process into a science and risk-based granulation end-point a myth, Powder Technology,
assessment. 189, 2009, 141–148.
[14]. Food and Drug Administration, Office of Generic
ACKNOWLEDGEMENT Drugs White Paper on Question-based Review:
http://www.fda.gov/cder/ OGD/QbR.htm.
I am thankful to Dr. C.N. Patel the principal of shri [15]. 19. Food and Drug Administration, Guidance for
sarvajanik pharmacy college, Mehsana, Gujrat, India for industry, Q6A specifications for new drug substances
providing the necessary facility for completing this review. and products: Chemical substances, 1999.
[16]. Woodcock J, The concept of pharmaceutical quality.
American Pharmaceutical Review, 7(6), 2004, 10–15.

IJISRT24FEB293 www.ijisrt.com 547

Volume 9, Issue 2, February – 2024 International Journal of Innovative Science and Research Technology
ISSN No:-2456-2165
[17]. Q10: Pharmaceutical Quality System, ICH Tripartite
Guidelines. International Conference on
Harmonization of Technical Requirements for
Registration of Pharmaceuticals for Human use,2007
[18]. FDA Guidance for Industry and Review Staff: Target
Product Profile – A Strategic Development Process
Tool (Draft Guidance)
[19]. Q8 (R1): Pharmaceutical Development, Revision 1,
ICH Harmonized Tripartite Guidelines, International
Conference on Harmonization of Technical
Requirements for Registration of Pharmaceuticals for
Human Use, 2007
[20]. Callis JB, Illman DL, Kowalski BR, Process
analytical chemistry.
[21]. Analytical Chemistry, 59, 1987, 624A–637A
[22]. Yu LX, Pharmaceutical quality by design: Product and
process development, understanding, and control.
Pharmaceutical Research, 25, 2008, 781–791.

IJISRT24FEB293 www.ijisrt.com 548